Pontine autosomal dominant microangiopathy and leukoencephalopathy (PADMAL): A Patient Guide
At a Glance
PADMAL is a rare inherited brain small-vessel disorder caused by a COL4A1 change. It mainly affects the pons, leading to slurred speech, clumsiness, and small ischemic strokes; care focuses on controlling vascular risks and weighing stroke against bleeding risk.
Pontine autosomal dominant microangiopathy and leukoencephalopathy, or PADMAL, is a rare genetic condition that specifically affects the smallest blood vessels in the brain [1]. It is driven by a unique change in the regulatory region (the 3’-UTR) of the COL4A1 gene [2]. This mutation acts like a broken “off switch,” causing the body to overproduce a structural protein called collagen. As this extra collagen builds up, it thickens the walls of the brain’s tiny vessels, gradually narrowing the space where blood can flow and making the vessel walls less flexible [3].
The disease primarily targets the pons, a vital structure in the brainstem that acts as a relay station for speech and movement signals. This focus on the brainstem is why the first signs of PADMAL—which typically appear between the ages of 30 and 50—often involve dysarthria, or slurred speech, and episodes of physical clumsiness or small ischemic strokes [4]. On an MRI, this process creates a highly characteristic pattern known as the “raisin bread” sign, where multiple tiny, oval-shaped spots appear in the pons, representing areas where blood flow was restricted [5].
Because the disease is progressive, the damage can slowly extend from the brainstem to the larger, upper parts of the brain, affecting coordination and cognitive processing speed over time [3]. However, the rate at which this happens varies significantly from person to person, even within the same family. Living with PADMAL involves a careful medical balancing act; while the narrowed vessels increase the risk of small ischemic strokes, they can also develop microbleeds. Therefore, decisions around using blood thinners or antiplatelet medications require highly individualized assessment by a neurologist [6].
Modern management of PADMAL focuses on aggressively protecting the blood vessels you have. Even though the disease is genetic, standard vascular risks like hypertension, smoking, and diabetes act as additional stress on your blood vessels and must be managed [7]. While the rarity of the diagnosis can feel isolating, understanding the biological mechanism of the disease allows you and your specialized care team to move forward with a clear plan. By focusing on individualized vascular health, proactive monitoring, and therapeutic support, you can take meaningful steps to manage the condition and maintain your quality of life [8].
In this guide
6 chapters
Understanding Your PADMAL Diagnosis
Learn what a PADMAL diagnosis means, including MRI findings, symptoms, COL4A1 genetics, stroke risks, and how doctors personalize monitoring and care for you.
Symptoms and Disease Progression of PADMAL
Learn how PADMAL symptoms progress, from dysarthria and small strokes to cognitive or swallowing problems, and why MRI changes cannot predict your course.
The Genetics and Biology of PADMAL
Learn how PADMAL affects COL4A1 regulation, how a 3'-UTR change disrupts miR-29 control, narrows brain vessels, and what dominant inheritance means for relatives.
How PADMAL is Diagnosed: MRI and Genetics
Learn how PADMAL is diagnosed using the MRI “raisin bread” sign, COL4A1 3′-UTR testing, genetic variant results, and checks for other common stroke causes.
Medical Management and Care for PADMAL
Learn how PADMAL treatment manages blood pressure, cholesterol, stroke and bleeding risks, blood thinners, and supportive therapies for speech and balance.
Daily Life, Care Team, and Emergencies
Learn how to manage daily life with PADMAL, build a coordinated care team, plan for family needs, recognize stroke warning signs, and respond to emergencies.
Common questions in this guide
What causes PADMAL?
What symptoms can PADMAL cause first?
What does the “raisin bread” sign mean on a PADMAL MRI?
Does PADMAL always get worse at the same rate?
How are stroke and bleeding risks balanced in PADMAL?
What can I do to protect my blood vessels with PADMAL?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How does my specific genetic variant compare to the classic PADMAL cases described in the literature?
- 2.What is my personalized target for blood pressure and cholesterol to best protect my blood vessels without reducing brain blood flow?
- 3.Who will be the primary neurologist coordinating my care and monitoring my imaging over time?
- 4.How should we balance my specific risks for ischemic stroke versus bleeding when considering any medications?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (8)
- 1
Cervical Spinal Involvement in a Chinese Pedigree With Pontine Autosomal Dominant Microangiopathy and Leukoencephalopathy Caused by a 3' Untranslated Region Mutation of COL4A1 Gene.
Zhao YY, Duan RN, Ji L, et al.
Stroke 2019; (50(9)):2307-2313 doi:10.1161/STROKEAHA.119.024875.
PMID: 31366314 - 2
Disruption of a miR-29 binding site leading to COL4A1 upregulation causes pontine autosomal dominant microangiopathy with leukoencephalopathy.
Verdura E, Hervé D, Bergametti F, et al.
Annals of neurology 2016; (80(5)):741-753 doi:10.1002/ana.24782.
PMID: 27666438 - 3
A Novel Mutation in COL4A1 Gene in a Chinese Family with Pontine Autosomal Dominant Microangiopathy and Leukoencephalopathy.
Li Q, Wang C, Li W, et al.
Translational stroke research 2022; (13(2)):238-244 doi:10.1007/s12975-021-00926-0.
PMID: 34415564 - 4
Pontine autosomal dominant microangiopathy with leukoencephalopathy: Col4A1 gene variants in the original family and sporadic stroke.
Roos J, Müller S, Giese A, et al.
Journal of neurology 2023; (270(5)):2631-2639 doi:10.1007/s00415-023-11590-9.
PMID: 36786861 - 5
'Raisin bread sign' feature of pontine autosomal dominant microangiopathy and leukoencephalopathy.
Kikumoto M, Kurashige T, Ohshita T, et al.
Brain communications 2023; (5(6)):fcad281 doi:10.1093/braincomms/fcad281.
PMID: 37953842 - 6
Recurrent Pontine Strokes in a Young Male.
Grobe-Einsler M, Urbach H, Paus S
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2020; (29(12)):105386 doi:10.1016/j.jstrokecerebrovasdis.2020.105386.
PMID: 33254373 - 7
ESO Guideline on covert cerebral small vessel disease.
Wardlaw JM, Debette S, Jokinen H, et al.
European stroke journal 2021; (6(2)):CXI-CLXII doi:10.1177/23969873211012132.
PMID: 34414301 - 8
Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology.
Mancuso M, Arnold M, Bersano A, et al.
European journal of neurology 2020; (27(6)):909-927 doi:10.1111/ene.14183.
PMID: 32196841
This PADMAL page is for informational purposes only and does not constitute medical advice. Your neurologist and care team should interpret your genetic results, MRI findings, and individualized stroke-versus-bleeding medication risks.
Get notified when new evidence is published on Pontine autosomal dominant microangiopathy with leukoencephalopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.